SABCS 2022 | The evolution of HER2-low breast cancer from primary to recurrence

Rani Bansal, MD, Duke Cancer Center, Durham, NC, discusses the evolution of HER2-low breast cancer from primary to recurrence, including data presented at the San Antonio Breast Cancer Symposium (SABCS) 2022 showing HER2 status can change following neoadjuvant therapy which could suggest changes in prognosis. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.